Match!
Erkut Borazanci
Translational Genomics Research Institute
CancerPathologyPancreatic cancerAdenocarcinomaMedicine
80Publications
8H-index
200Citations
What is this?
Publications 86
Newest
#1Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
#2Michael J Pishvaian (JHUSOM: Johns Hopkins University School of Medicine)
view all 5 authors...
Source
#1Katherine M. Bever (Johns Hopkins University)H-Index: 4
#2Erkut BorazanciH-Index: 8
Last. Ana De Jesus-Acosta (Johns Hopkins University)H-Index: 13
view all 18 authors...
700Background: Few studies have examined maintenance therapy in unselected pts with metastatic PDA (mPDA). mTOR signaling is central to several oncogenic pathways in PDA and also has a role in T ce...
Source
#1Kimberly Perez (Harvard University)H-Index: 5
#1Kimberly Perez (Harvard University)H-Index: 10
Last. David A. Tuveson (CSHL: Cold Spring Harbor Laboratory)H-Index: 71
view all 18 authors...
TPS784Background: Patients(pts) with metastatic pancreatic cancer (PC) have a median survival of less than one year even with use of multiagent chemotherapy programs. Pancreatic tumors are composed...
Source
#1Marc Roth (Vandy: Vanderbilt University)H-Index: 1
#2Dana Backlund Cardin (Vandy: Vanderbilt University)H-Index: 10
Last. Jordan Berlin (Vandy: Vanderbilt University)H-Index: 51
view all 9 authors...
698Background: Survival statistics for mPDA are dismal and with limited treatment options novel agents are needed to improve disease outcomes. PBI-05204 (Phoenix Biotechnology, Inc., San Antonio, T...
Source
#1Erkut BorazanciH-Index: 8
#2Ronald L. KornH-Index: 14
Last. Gayle S. JamesonH-Index: 12
view all 10 authors...
Source
#1Gayle S. Jameson (TGen: Translational Genomics Research Institute)H-Index: 12
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
view all 16 authors...
Importance Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations, indicating a DNA repair deficiency associated with sensitivity to DNA damaging agents, such as platinum. Objective To determine response rate following treatment with nab-paclitaxel plus gemcitabine plus platinum-based cisplatin for patients with metastatic pancreatic ductal adenocarcinoma (PDA). Design, Setting, and Participants This was a single-arm, open-label, phase 1b/2 clinical trial of nab...
1 CitationsSource
#1Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
#2Gayle S. Jameson (TGen: Translational Genomics Research Institute)H-Index: 12
view all 16 authors...
Background: Localized PDAC management has recently evolved. Due to concerns over micrometastases at diagnosis, the use of neoadjuvant chemotherapy for PDAC has become more common. Typical therapies involve the use of multiagent systemic chemotherapy with or without radiation therapy. Cancer antigen 19-9 (CA 19-9) normalization in borderline resectable (BR) and locally advanced (LA) PDAC has been associated with greater OS. The addition of cisplatin (C) to gemcitabine (G) and paclitaxel protein b...
Source
#1Sarah K. Highlander (TGen: Translational Genomics Research Institute)
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
view all 8 authors...
Background: Pancreatic cancer remains a deadly disease, and immunotherapy is effective in only 1-2% of microsatellite instability-high pancreatic cancers. The response to immunotherapy is very heterogeneous across tumor types, but recently there is evidence that the gastrointestinal microbiome may influence the response to immunotherapy. The SU2C Catalyst Trial is a randomized phase II maintenance trial to compare outcomes using a combination regimen of the vitamin D agonist, paricalcitol, plus ...
Source
#1Manuel Hidalgo (Cornell University)H-Index: 2
#1M. Hidalgo (Cornell University)H-Index: 1
Last. Teresa MacarullaH-Index: 27
view all 16 authors...
Abstract Background Current treatment options for PDAC are limited. While PD-1/PD-L1 antagonists have shown promising results in other cancer types, this approach has been ineffective in PDAC. In Cohort 1 of the COMBAT study, the dual combination of BL-8040 (a CXCR4 inhibitor) and Pembrolizumab was safe and showed a promising 7.5 mo OS in 2L patients. BL-8040 modified the TME by promoting infiltration of effector T cells and decreasing immune suppressor cells. Based on these encouraging results,...
3 CitationsSource
#2Rolf HultschH-Index: 1
Last. Erkut BorazanciH-Index: 8
view all 6 authors...
Background: Thrombocytopenia may be a concern in treating pancreatic ductal adenocarcinomas (PDAC). Due to anatomic position these tumors commonly cause narrowing or occlusion of the splenic vein which may lead to hypersplenism and thrombocytopenia due to sequestration. PDAC patients with thrombocytopenia have limited options for treatment. Partial splenic embolization (PSE) is a procedure developed as an alternative to splenectomy in individuals with hypersplenism. The purpose of our study was ...
Source
123456789